La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Abbott Laboratories Gestion

Gestion contrôle des critères 3/4

Le PDG Abbott Laboratories' est Robert Ford, nommé en Oct2018, a un mandat de 5.83 ans. La rémunération annuelle totale est $ 23.27M, composée du salaire de 6.4% et des bonus 93.6%, y compris les actions et options de la société. détient directement 0.024% des actions de la société, d'une valeur de CLP 42.58B. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.6 ans et 5.5 ans.

Informations clés

Robert Ford

Directeur général

US$23.3m

Rémunération totale

Pourcentage du salaire du PDG	6.4%
Durée du mandat du directeur général	5.9yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	5.7yrs
Durée moyenne du mandat des membres du conseil d'administration	5.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Robert Ford a-t-elle évolué par rapport aux bénéfices de Abbott Laboratories?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Rémunération vs marché: La rémunération totale de Robert ($USD 23.27M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché CL ($USD 6.09M ).

Rémunération et revenus: La rémunération de Robert a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Robert Ford (50 yo)

5.9yrs

Titularisation

US$23,268,171

Compensation

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Robert Ford	Chairman of the Board	5.9yrs	US$23.27m	0.024% $ 42.4b
Philip Boudreau	CFO & Executive VP of Finance	less than a year	US$3.32m	0.0023% $ 4.0b
Hubert Allen	Executive VP	11.7yrs	US$7.42m	0.011% $ 18.8b
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10yrs	US$5.93m	0.0072% $ 12.8b
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.7yrs	US$5.50m	0.0035% $ 6.2b
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	pas de données	pas de données
Michael Comilla	Vice President of Investor Relations.	no data	pas de données	pas de données
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	pas de données	pas de données
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	pas de données	pas de données
Christopher Scoggins	Senior Vice President of Commercial Operations	1.7yrs	pas de données	pas de données
Mary Moreland	Executive Vice President of Human Resources	5.1yrs	pas de données	0.0059% $ 10.4b
Jared Watkin	Executive Vice President of Diabetes Care	9.3yrs	pas de données	0.0041% $ 7.3b

5.7yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ABTCL est chevronnée et expérimentée (ancienneté moyenne 5.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Robert Ford	Chairman of the Board	4.8yrs	US$23.27m	0.024% $ 42.4b
Daniel Starks	Independent Director	7.6yrs	US$349.29k	0.39% $ 681.4b
John Stratton	Independent Director	7.7yrs	US$341.96k	0.00020% $ 353.3m
Nancy McKinstry	Lead Independent Director	12.8yrs	US$405.96k	0.00027% $ 477.0m
Michael Roman	Independent Director	3.4yrs	US$337.96k	0% $ 0
Robert Alpern	Independent Director	15.9yrs	US$441.44k	0% $ 0
Michael O'Grady	Independent Director	1.4yrs	US$283.96k	0% $ 0
Michelle Kumbier	Independent Director	6.3yrs	US$331.96k	0.00018% $ 318.0m
Sally Blount	Independent Director	12.8yrs	US$362.60k	0.00015% $ 265.0m
Claire Babineaux-Fontenot	Independent Director	2yrs	US$354.96k	0% $ 0
Darren McDew	Independent Director	5yrs	US$331.19k	0% $ 0
Patricia Gonzalez	Independent Director	3.1yrs	US$356.96k	0% $ 0

5.6yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ABTCL sont considérés comme expérimentés (ancienneté moyenne 5.5 ans).

Abbott Laboratories Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Insider recently sold CL$2.9m worth of stock

Insider recently sold CL$2.3b worth of stock

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Insider recently sold CL$111m worth of stock

Independent Director recently sold CL$4.4b worth of stock

Insider recently sold CL$490m worth of stock

Recent updates

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Insider recently sold CL$2.9m worth of stock

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Second quarter 2024 earnings released: EPS: US$0.74 (vs US$0.79 in 2Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

First quarter dividend of US$0.55 announced

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Insider recently sold CL$2.3b worth of stock

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.76 in 1Q 2023)

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.75 in 1Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Insider recently sold CL$111m worth of stock

Fourth quarter dividend of US$0.55 announced

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Now 30% overvalued after recent price rise

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings released: EPS: US$3.27 (vs US$3.94 in FY 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold CL$4.4b worth of stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.81 in 3Q 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Upcoming dividend of US$0.51 per share at 2.1% yield

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Insider recently sold CL$490m worth of stock

Independent Director recently sold CL$4.7b worth of stock

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: US$0.79 (vs US$1.15 in 2Q 2022)

Upcoming dividend of US$0.51 per share at 1.9% yield

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen